Fermenta Biotech Ltd · NSE:FERMENTA
Fermenta Biotech — Investor Presentation (November 2020)
34 slides from Fermenta Biotech's investor presentation, Nov 23, 2020
Slide 1: Intimation of Investor Relations Presentation to BSE
Ref: F.No.:49 November 23, 2020 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Investor Relations Presentation – November 2020 Ref: Scrip Code: 506414 Pursuant to the relevant provisions of SEBI (Listing Obligations and
Slide 2: Investor Presentation | November 2020
Investor Presentation | November 2020
Slide 3: Snapshot
Snapshot Top 3 Only manufacturer of Amongst top 3 manufacturers Global Presence in Vitamin D3 in India of Vitamin D3 globally 50+ countries Proprietary technology to 50 Years of Vitamin D3 2 Manufacturing Plants manufacture Vitamin D3 manufacturing experience registered with US-FDA (FFRM) DSIR appro
Slide 4: Company Overview
Company Overview • Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is Operational Revenue (INR Mn) & engaged in development and manufacturing of pharmaceuticals, biotechnology and Operational EBITDA Margin (%) environmental solutions used across various indu
Slide 5: Board Of Directors
Board Of Directors Mr. Sanjay Buch - Chairman (Independent Director) Ms. Rajeshwari Datla (Non-Executive Director) • He holds a Bachelors Degree in Economics and Law and has over two • A Science graduate having a rich experience in the Pharmaceutical Industry. decades of experience in wide spectrum
Slide 6: Awards and Recognitions
Awards and Recognitions India Pharma Awards 2018 Excellence in CSR Excellence in Export Pharma International Promotion Excellence Chief Strategy Officer Summit & Business Excellence Hindustan Times Best Business Brands Awards 2020 Awards 2019 Thane Ratna Award 2020 2020 Fermenta Biotech Limited 5
Slide 7: FBL Features in the Media
FBL Features in the Media Zee Business Growth Forum Economic Times supplement May 2019 dated 20th August 2019 Forbes India issue dated 30th ET Now interview telecast on its morning August 2019 prime time show on 6th January 2020 Fermenta Biotech Limited 6
Slide 8: Milestones
Milestones Leased land at Saykha for future expansion Enhanced Vitamin D3 --- Fermenta Biotech Ltd capacity at Dahej Merger of DIL and FBL was established with its first Second plant for --- completed Establishment of enzyme manufacturing manufacturing of Vitamin Launched new version of --- Internat
Slide 9: Geographical Presence
Geographical Presence Kullu Fermenta Biotech GmbH Fermenta Biotech USA LLC Dahej, Saykha Thane Geographical Revenue Mix % (FY20) for Vit D3 and Other API India ROW 27% R&D Centre and Registered Office 27% Manufacturing Facility USA Europe 11% Regions Present 34% Fermenta Biotech Limited 8
Slide 10: Manufacturing Plants
Manufacturing Plants Kullu (Himachal Pradesh) • Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Acylase enzyme. A new bulk drug division in 2004 to manufacture various APIs like Vitamin D3, Phenyramidol HCI and Silicon Powder. • This plant is certified by HALAL, KOSHER, Vege
Slide 11: Accreditations & Certifications
Accreditations & Certifications* *Accreditations & Certifications are products / site specific Fermenta Biotech Limited 10
Slide 12: R&D and Quality
R&D and Quality R&D • Modern, fully equipped, DSIR approved Research & Development facility complemented by highly skilled and committed scientists. • Providing integrated solutions, processes and products for Biotech and Active Pharmaceutical Ingredients (API) • API R&D, combined with expertise on
Slide 13: New Patents Filed
New Patents Filed Irradiation Process Of Pro Vitamin D Novel Method For Synthesizing 25-OH An Improved Process To Synthesize Cholesterol/Calcifediol 5-(3-Pyridyl)-2, 2’-Bithiophene (Sensitizer) From Phytosterol Improved Cost Effective Process for Improved Photochemical Synthesis Of Vitamin D3 Using
Slide 14: Business Overview
BUSINESS OVERVIEW
Slide 15: About Vitamin D3
About Vitamin D3 For Humans • Vitamin D3 (Cholecalciferol) is a fat- • Vitamin D has been linked to a multitude of health benefits such as soluble vitamin, responsible for calcium general health and wellbeing, bone and mental health as well as absorption in the body. management and prevention of cer
Slide 16: FBL in Vitamin D3
FBL in Vitamin D3 CAGR Growth FY15 to FY20 Vitamin D3 Revenue (INR Mn) 3,228 23% 20% 2,392 • FBL is a leader in manufacturing Vitamin D3, and has 2,334 the distinction of being the only organization in India 15% 69% 1,601 to manufacture Vitamin D3 10% 67% 56% 44% • The company has a Non-China depend
Slide 17: Manufacturing Process and Applications
Manufacturing Process and Applications Backward Integrated Manufacturing Process Vitamin D3 Applications Sheep Wool Scouring of Wool For Humans Cleaned Wool Wool Grease Pharmaceuticals Dietary and Nutritional Supplements Food and Drinks Fortification Lanolin Cholesterol For Animals 7-Dehydrocholeste
Slide 18: Other Segments
Other Segments Active Environmental Solutions Pharmaceutical • FBL’s Environmental Solutions provide Ingredients (APIs) unique advantages in waste water treatment and management through • For over 25 years, the integrated biotechnology. Company is a trusted and reliable source of Phenyramidol HCl (m
Slide 19: Expanding Our Nutraceutical Basket
Expanding Our Nutraceutical Basket • From single Vitamin D3 to multi-vitamin, the company aims to widen its nutraceuticals ingredients basket within the next 5 years • Developing new technologies enabling FBL to get into value-added ingredients, improving stability, bioavailability and scalability •
Slide 20: Nutraceutical Product Pipeline
Nutraceutical Product Pipeline Vitamin D3 and its various formats for Variants of Fat soluble vitamins Other Nutraceuticals Pharmaceuticals Vitamin A Smart Minerals Dietary & Nutritional Supplements Food Vitamin E Novel Anti-oxidants Feed Vitamin D2 Pre and Pro - Biotics Veterinary Science Rodentici
Slide 21: Growth Drivers
Growth Drivers Internal Factors • Strong manufacturing capabilities with enhanced capacity utilizations to meet YoY production targets • Enhancing control and reduced dependence by backward integration World- • Sales footprint in 50+ countries spread across the globe Class Innovation Facilities • Ex
Slide 22: Strategic Initiatives
Strategic Initiatives ➢ Enhanced Focus – Exiting of non-core business activities and laying long term emphasis on expanding the Nutraceutical business. ➢ Capital Allocation Plans – All future capital allocation will be focused towards Nutraceuticals business. ➢ Real Estate Business – The company is
Slide 23: Industry Overview
INDUSTRY OVERVIEW
Slide 24: Vitamin D Industry
Vitamin D Industry • The Vitamin D market is estimated to account for about USD 1.1 billion in 2019 and is projected to reach Market size of vitamins and CAGR a value of nearly USD 1.7 billion by 2025, growing at a CAGR of 7.0% from 2019 to 2025. 5-year MAT Value MAT Value value July 2014 July 2018
Slide 25: Importance of Vitamin D in Covid-19
Importance of Vitamin D in Covid-19 To read the articles, please click on the respective image New study shows vitamin D may be Vitamin D supplement cheap, effective treatment for COVID- 19, can reduce risk of hospitalisation calcifediol could reduce death risk in Covid patients, Spanish study says
Slide 26: Vitamin D3 Animal Feed Price Trend
Vitamin D3 500 Animal Feed Price Trend Vitamin D3 500 Price Trend Euro/Kg 100.00 Min of Low Max of High 90.00 85.00 80.00 80.00 75.00 70.00 60.00 60.00 50.00 50.00 40.00 33.00 32.00 30.00 30.00 25.00 22.00 22.00 21.00 20.00 18.00 20.00 12.50 8.00 9.25 7.60 6.25 6.70 10.00 5.60 6.00 0.00 2012 2013 20
Slide 27: Nutraceutical Industry
Nutraceutical Industry • The USA, Japan and Europe account for more than 90% of the total global nutraceutical market. Global Nutraceutical Market Size (USD Bn) 578.2 • North America nutraceuticals market is a mature market and is likely to progress at a CAGR of 531.3 over 7.8% from 2016 to 2024. In
Slide 28: Financial Overview
FINANCIAL OVERVIEW
Slide 29: Historical Standalone Income Statement (Ind-AS)
Historical Standalone Income Statement (Ind-AS) PARTICULARS (INR Mn) FY19 FY20 H1-FY21 Operational Revenue 4,047 3,005 1,942 Total Expenses 2,634 2,311 1,417 Operational EBITDA 1,413 694 525 Operational EBITDA Margin (%) 34.91% 23.09% 27.03% Other Income 123 123 22 Depreciation 119 149 84 Finance Co
Slide 30: Standalone Balance Sheet (Ind-AS)
Standalone Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY19 FY20 H1-FY21 PARTICULARS6069 (INR Mn) FY19 FY20 H1-FY21 Equity 2,495 3,126 3,467 Assets a) Equity share capital 46 144 144 Non-current Assets 2,557 3,272 3,408 b) Share Pending issuance 2 - - a) Property, plant and equipment 972 1,040 1,558
Slide 31: Historical Consolidated Income Statement (Ind-AS)
Historical Consolidated Income Statement (Ind-AS) PARTICULARS (INR Mn) FY18 FY19 FY20 H1-FY21 Operational Revenue 3,030 4,047 2,929 1,878 Total Expenses 2,100 2,558 2,277 1,385 Operational EBITDA 930 1,489 652 493 Operational EBITDA Margin (%) 30.69% 36.79% 22.26% 26.25% Other Income 89 124 123 29 D
Slide 32: Consolidated Balance Sheet (Ind-AS)
Consolidated Balance Sheet (Ind-AS) PARTICULARS (INR Mn) FY19 FY20 H1-FY21 PARTICULARS (INR Mn) FY19 FY20 H1-FY21 Equity 2,506 3,094 3,406 Assets a) Equity share capital 46 144 144 Non-current Assets 2,556 3,297 3,431 b) Share Pending issuance 2 - a) Property, plant and equipment 973 1,040 1,559 c)
Slide 33: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance Operational EBITDA (INR Mn) & PAT (INR Mn) & PAT Margins (%) Operational Revenue (INR Mn) Operational EBITDA Margins (%) 37% 29% 31% 22% 4,047 20% 1,489 15% 1,175 3,030 2,929 930 652 595 463 FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20 EBITDA (INR Mn) EB
Slide 34: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Fermenta Biotech — Investor Presentation (November 2020) on 6ix